Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2023, Vol. 28 ›› Issue (4): 419-428.doi: 10.12092/j.issn.1009-2501.2023.04.009

Previous Articles     Next Articles

Advances in clinical research on drug-induced acute interstitial nephritis

ZHANG Mingkang1,2,3, MA Yanrong1,3, JIN Yongwen1,3, ZHOU Yan1,3, CUI Ruirui1,2,3, WU Xin'an1,2,3   

  1. 1Department of Pharmacy, First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China; 2School of Pharmacy, Lanzhou University, Lanzhou 730020, Gansu, China; 3Engineering Research Centre of Prevention and Control Risk for Clinical Medicine of Gansu Province, Lanzhou 730000, Gansu, China 
  • Received:2022-12-06 Revised:2023-03-09 Online:2023-04-26 Published:2023-05-17

Abstract:

The kidneys are one of the main excretory organs for drugs and when drugs are not excreted effectively, they can accumulate in the kid- neys or in the interstitial tubules, leading to drug-induced kidney injury. The tubulointerstitium accounts for 80% of the volume of the kidney and is the primary site of response to various types of renal injury. This article focuses on drug-induced acute interstitial nephritis, highlighting its clinical symptoms, listing common induction drugs, analysing pathological features, and explaining its pathogenesis from the perspective of immune response, with the aim of providing a basic and clinical evidence for subsequent studies.

Key words: drug-induced acute interstitial nephritis, clinical symptoms, induction drugs, pathological features, pathogenesis

CLC Number: